Drug profile · INN
axitinib
INLYTA
axitinib (INLYTA) is a vascular endothelial growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — axitinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 10
- Data quality
- 0.89
Quick answer
axitinib (INLYTA) is a vascular endothelial growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Vascular endothelial growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is axitinib?
axitinib (INLYTA) is a vascular endothelial growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for axitinib?
INLYTA is a marketed brand name for axitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of axitinib?
axitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.